Jci_page_head_homepage_01 Jci_page_head_homepage_02
Erica L. McCoy, Ritsuko Iwanaga, Paul Jedlicka, Nee-Shamo Abbey, Lewis A. Chodosh, Karen A. Heichman, Alana L. Welm, Heide L. Ford
Published in Volume 119, Issue 9
J Clin Invest. 2009; 119(9):2663–2677 doi:10.1172/JCI37691
Abstract | Full text | PDF | Supplemental material
Options: View larger image (or click on image)
Jci37691
Figure 9
Six1 overexpression significantly correlates with poor clinical outcome in breast cancers, and this significance is increased by coexpression of Ccnd1.

(A) In a study of 295 women with early-stage invasive breast carcinoma (45), high Six1 expression is associated with shortened time to metastasis, shortened time to relapse, and shortened breast cancer–specific survival (survival) (48). (B) In the same dataset, Ccnd1 overexpression alone does not correlate with shortened time to metastasis or relapse, or with shortened survival. (C) When Six1 and Ccnd1 are both overexpressed, their correlation to clinical parameters is exacerbated and the significance for poor prognosis is increased. (D) In a study of 240 patients diagnosed with invasive breast cancer of any stage (Pawitan and Ivshina) (46, 47), high Six1 expression is strongly associated with shortened time to relapse (48). Ccnd1 overexpression alone has no correlation with shortened time to relapse. When Six1 and Ccnd1 are both overexpressed, their correlation to shortened time to relapse is more significant. In both of these datasets, the mean value for Six1 and Ccnd1 expression in human breast cancers was used to divide the patients into high (above mean) and low (below mean) Six1– and Ccnd1–expressing animals.